Heartbeam, Inc. · NASDAQ:BEAT
Heartbeam — Q3 2022 Earnings Presentation
17 slides from Heartbeam's earnings presentation, Nov 10, 2022
Slide 1: Heart Attack Detection
Heart Attack Detection Third Quarter 2022 Financial Results Conference Call NASDAQ: BEAT November 10, 2022
Slide 2: Disclaimers
Third Quarter 2022 Financial Results Conference Call DISCLAIMERS This presentation contains forward-looking statements. All statements other than statements of historical fact contained in this presentation, including statements as to the Company’s future results of operations and financial position
Slide 3: Agenda
Third Quarter 2022 Financial Results Conference Call Agenda • Introduction and Recent Announcements Branislav Vajdic • Product Timelines and Updates, and Partnerships Jon Hunt • Model at Scale and Financial Results Rick Brounstein • Closing Summary Branislav Vajdic 30 years of experience 34 years’ e
Slide 4: Video: HeartBeam AIMIGo Technology
Third Quarter 2022 Financial Results Conference Call Video: HeartBeam AIMIGo™ Technology Video link will open in web browser 4
Slide 5: No Patient Friendly Heart Attack Solution in the Market
Third Quarter 2022 Financial Results Conference Call No Patient Friendly Heart Attack Solution in the Market 5
Slide 6: Key Third Quarter 2022 and Subsequent Highlights
Third Quarter 2022 Financial Results Conference Call Key Third Quarter 2022 and Subsequent Highlights • 510(k) application for HeartBeam AIMI™ platform to FDA to aid in diagnosis of heart attack submitted in August, with expected clearance in the fourth quarter and limited market release in Q1 2023
Slide 7: HeartBeam AIMI Updates
Third Quarter 2022 Financial Results Conference Call HeartBeam AIMI Updates • Submission of HeartBeam AIMI platform to FDA to aid in diagnosis of heart attack in August, with expected clearance in the fourth quarter and limited market release in Q1 2023 • Expanded the addressable patient population
Slide 8: AIMI Software Product First Revenues
Third Quarter 2022 Financial Results Conference Call HeartBeam AIMI Software Product First Revenues HeartBeam’s software-only heart attack diagnosis tool for the Emergency Department Software licensing business model improves accuracy of MI diagnosis drives $100k/year per Emergency 93% Department No
Slide 9: AIMI Software and AIMIGo Revenue Opportunity
Third Quarter 2022 Financial Results Conference Call HeartBeam AIMI Software and Gen. 1 HeartBeam AIMIGo Revenue Opportunity HeartBeam AIMI HeartBeam AIMI™ GEN 1 HeartBeam AIMIGo HeartBeam SOFTWARE SOLUTION HeartBeam will use its own salesforce AIMIGo™ HeartBeam will use its own salesforce Excellent
Slide 10: HeartBeam AIMIGo Updates
Third Quarter 2022 Financial Results Conference Call HeartBeam AIMIGo Updates • Broadened product portfolio pipeline with smartwatch connectivity supporting a daily heart monitoring solution, leveraging the HeartBeam AIMIGo platform • Granted patent for signal transformation from VECG to 12-Lead Ele
Slide 11: AIMIGo Product Development and Regulatory Plan
Third Quarter 2022 Financial Results Conference Call HeartBeam AIMIGo Product Development and Regulatory Plan 3D Vector Cardiogram FDA 510(K) HeartBeam Credit card sized AIMIGo™ collection device Predicate devices identified GEN 1 Smartphone app Simple validation study Synthesized baseline + Q3 2022
Slide 12: AIMIGo Product Reimbursement Strategy
Third Quarter 2022 Financial Results Conference Call HeartBeam AIMIGo Product Reimbursement Strategy Use Available RPM Codes to Accelerate Revenue and Data Collection Utilize existing RPM* Codes Basic Gen 1 CPT Codes Description MPFS** Remote monitoring of physiologic Excellent alignment with 99453
Slide 13: Market Landscape: Substantial Capabilities Beyond Existing Offerings
Third Quarter 2022 Financial Results Conference Call Market Landscape Substantial Capabilities Beyond Existing Offerings Heart Attack Detection 12L ECG Capable Integrates history & symptoms Uses Baseline Long Term Use Potential AFib Detection AFlutter Detection 13
Slide 14: Sample Financial Model for AIMI & AIMIGo Solutions at Scale
Third Quarter 2022 Financial Results Conference Call Sample Financial Model for our HeartBeam AIMI & HeartBeam AIMIGo Solutions at Scale Revenue at TAM Penetration % Sample Financial Model $25M Sample Financial Model $100M $ in Thousands HeartBeam AIMI™ HeartBeam AIMIGo™ Total HeartBeam AIMI™ HeartB
Slide 15: Q3 2022 Financial Highlights
Third Quarter 2022 Financial Results Conference Call Q3 2022 Financial Highlights $ in Thousands Quarters ended September 30, 2022 2021 Operating Expenses: General & Administrative $2,048 $341 Research & Development 1,562 105 Total Operating Expenses 3,610 446 Loss from Operations (3,610) (446) Inte
Slide 16: Closing Summary
Third Quarter 2022 Financial Results Conference Call Closing Summary • Well known and previously unsolved problem with a massive worldwide market • Product timeline and milestones on track for FDA Clearance and market launch • HeartBeam AIMI™ platform August submission to FDA to aid in diagnosis of
Slide 17: Q&A
Q&A Company Investor Relations Rick Brounstein Chris Tyson Chief Financial Officer Executive Vice President HeartBeam, Inc. MZ North America ir@heartbeam.com Direct: 949-491-8235 BEAT@mzgroup.us www.mzgroup.us www.heartbeam.com 2118 Walsh Avenue, Suite 210 Santa Clara, CA 95050